☆ 4.7 Article

First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma

Lorena Perez-Amill et al.

Summary: This study developed CAR-T cells targeting multiple myeloma, with ARI2h cells showing superior therapeutic efficacy compared to ARI2m cells, especially in cases with high tumor burden disease. The humanization of the single chain variable fragment and large-scale expansion of CAR-T cells set the groundwork for a clinical trial to evaluate the efficacy of ARI2h cell treatment for multiple myeloma patients.

HAEMATOLOGICA (2021)

添加到收藏夹

Article Medicine, General & Internal

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

E. Kastritis et al.

Summary: In patients with newly diagnosed AL amyloidosis, adding daratumumab to bortezomib, cyclophosphamide, and dexamethasone resulted in higher rates of hematologic complete response and improved survival outcomes. However, adverse events, including lymphopenia, pneumonia, cardiac failure, and diarrhea, were more common in the daratumumab group. Most deaths were due to amyloidosis-related cardiomyopathy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Hematology